// App-Quantinova.ai

827 : The role of combination immune checkpoint inhibitors as salvage therapy for PD-1/PD-L1-resistant merkel cell carcinoma

Researchers

Presenter

  • Tarek Haykal

Principal Investigators

  • Georgia Beasley

  • April Salama

  • Brent Hanks

Medical Centers

  • Duke University, Duham, United States

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Merkel cell carcinoma

  • Solid malignancies

Biomarkers

  • Programmed cell death protein 1

Drug/Treatment

  • Pembrolizumab

  • Ipilimumab

  • Nivolumab

  • Avelumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved